Solid Tumor Malignancies

Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

DS
Daiichi SankyoChina - Shanghai
1 program
1
Valemetostat TosylatePhase 21 trial
Active Trials
NCT07303387Not Yet Recruiting900Est. Feb 2032
Vir Biotechnology
Vir BiotechnologyCA - San Francisco
1 program
1
VIR-5525Phase 11 trial
Active Trials
NCT06960395RecruitingEst. Aug 2029
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
Expert ReviewN/A1 trial
Active Trials
NCT06896162Recruiting500Est. Jun 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
2031
Daiichi SankyoValemetostat Tosylate
Vir BiotechnologyVIR-5525
Eli Lilly and CompanyExpert Review

Clinical Trials (3)

Total enrollment: 1,400 patients across 3 trials

NCT07303387Daiichi SankyoValemetostat Tosylate

Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

Start: Feb 2026Est. completion: Feb 2032900 patients
Phase 2Not Yet Recruiting

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Start: Jul 2025Est. completion: Aug 2029
Phase 1Recruiting

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Start: Jun 2025Est. completion: Jun 2028500 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,400 patients
3 companies competing in this space